INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020
INOVIO (NASDAQ: INO) will release its third-quarter 2020 financial results after market close on November 9, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide updates on its DNA Medicines Platform, including ongoing COVID-19 vaccine developments. Currently, INOVIO has 15 DNA medicine clinical programs targeting HPV-associated diseases, cancer, and infectious diseases. The company's innovative approach utilizes the CELLECTRA device for efficient delivery of DNA medicines, showing promise in clinical trials involving over 2,000 patients.
- Scheduled financial results release on November 9, 2020, shows proactive communication.
- Ongoing vaccine development for COVID-19 under grants from CEPI and the Department of Defense.
- Strong clinical track record with over 15 active clinical programs.
- CELLECTRA device enhances delivery efficiency and has shown robust immune responses in trials.
- None.
PLYMOUTH MEETING, Pa., Oct. 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
About INOVIO's DNA Medicines Platform
INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA®. The simple-to-use CELLECTRA device provides a brief electrical pulse to reversibly open small pores in the local skin area cells resulting in more than a hundred-fold increase in product delivery providing dose sparing and consistency. Once inside the cell, the DNA plasmids instruct the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers specific T cell and antibody-mediated immune responses. Administration with the CELLECTRA device, which takes only a few seconds, is designed to ensure that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive the immune responses. INOVIO's DNA medicines are transient, and do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the consistent immune response, safety profile, and tolerability that have been observed in clinical trials with multiple products.
With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce an efficacious, robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for
CONTACTS:
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
View original content:http://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2020-financial-results-on-november-9-2020-301159344.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When will INOVIO release their third-quarter 2020 financial results?
What time is the INOVIO conference call scheduled for?
What clinical programs does INOVIO currently have in development?
What is the CELLECTRA device used for?